EPC 004
Alternative Names: EPC-004Latest Information Update: 28 Apr 2025
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA (Parenteral)
- 14 Apr 2023 Preclinical trials in Multiple myeloma in USA (Parenteral)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Multiple myeloma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)